GO
Loading...

Merck & Co Inc

More

  • US STOCKS-Futures fall after soft China, Japan data Monday, 8 Dec 2014 | 7:37 AM ET

    NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from a record high, as soft data in China and Japan stoked global growth concerns. *Merck& Co Inc said it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion. *European shares were lower after the data from China and Japan.

  • Merck dives into 'superbug' chase with Cubist Monday, 8 Dec 2014 | 7:25 AM ET

    Merck will spend $8.4 billion to buy Cubist Pharmaceuticals and move deeper into treating so-called "superbugs" that have drawn dire warnings from global health organizations. Antibiotic-resistant infections are linked to 23,000 deaths and 2 million illnesses in the United States annually, according to the Centers for Disease Control and Prevention.

  • Merck to buy Cubist in $9.5 billion deal  Monday, 8 Dec 2014 | 7:01 AM ET

    CNBC's Meg Tirrell reports on Merck's plans to acquire Cubist.

  • Asian stocks fall on growth concerns Monday, 8 Dec 2014 | 2:13 AM ET

    Weak trade figures out of China and news that Japan's recession is deeper than initially thought suggested demand for crude would be lower in those two economies. Among the big losers were two Dow Jones industrial average components, Chevron, down 3.7 percent, and Exxon Mobil, off 2.3 percent. "When you look at the major drivers of global growth— Japan, China and the...

  • Dec 6- Merck& Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer...

  • Dec 6- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. Margaret Shipp, co-lead investigator of the Checkmate-039 study from Dana-Farber Cancer Institute in Boston. The results were being...

  • Merck in talks to buy Cubist for over $8B Friday, 5 Dec 2014 | 11:51 PM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Drug giant Merck is in talks to acquire antibiotics maker Cubist for about $102 a share in cash, according to people familiar with the matter.

  • Ebola booster vaccine starts first trials in Oxford Thursday, 4 Dec 2014 | 4:25 AM ET

    LONDON, Dec 4- Scientists at Oxford University have launched the first clinical tests of a new Ebola vaccine approach, using a booster developed by Denmark's Bavarian Nordic that may improve the effects of a shot from GlaxoSmithKline. Thirty healthy volunteers in Britain who have already received the experimental Ebola vaccine being developed by GSK and the...

  • Dec 2- Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study. Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs,...

  • Back for more: Will Pfizer top its AstraZeneca bid? Wednesday, 26 Nov 2014 | 3:34 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer’s $110 billion bid for AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • Nov 24- Merck& Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine. The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug. The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015..

  • Dow, S&P close at records; Intel up 4% Thursday, 20 Nov 2014 | 4:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed at highs after encouraging domestic data alleviated concerns over continued signs of slowing growth in Europe and China.

  • Stocks little moved; S&P 500 at record-high close Monday, 17 Nov 2014 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks fell Monday after data had Japan unexpectedly falling into a recession.

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...

  • Midday movers: Allergan, CarMax, CBS & more Monday, 17 Nov 2014 | 1:03 PM ET

    Some of Monday's midday movers:

  • CHICAGO, Nov 17- After years of uncertainty, a nearly decade-long study showed that Merck& Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. Christopher Cannon, lead investigator of the 18,144- patient Improve-It study presented at the American Heart Association...

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • European shares close higher after Draghi speaks Monday, 17 Nov 2014 | 11:44 AM ET

    European shares closed higher after ECB President Mario Draghi reiterated that he was willing to do more to stimulate the euro zone economy.

  • Stock futures decline as Japan slides into recession Monday, 17 Nov 2014 | 9:17 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.